Atara Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Atara Biotherapeutics
ATRA Stock  USD 17.25  2.31  15.46%   
Atara Biotherapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Atara Biotherapeutics' valuation are provided below:
Gross Profit
71 M
Profit Margin
0.154
Market Capitalization
107.7 M
Enterprise Value Revenue
0.71
Revenue
151.9 M
We have found one hundred twenty available fundamental signals for Atara Biotherapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Atara Biotherapeutics prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 95.3 M, whereas Enterprise Value is forecasted to decline to about 86.6 M.

Atara Biotherapeutics Total Revenue

155.7 Million

Check Atara Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atara Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.1 M, Selling General Administrative of 47 M or Other Operating Expenses of 199.2 M, as well as many indicators such as Price To Sales Ratio of 0.84, Dividend Yield of 0.0 or Days Sales Outstanding of 3.59. Atara financial statements analysis is a perfect complement when working with Atara Biotherapeutics Valuation or Volatility modules.
  
Build AI portfolio with Atara Stock
Check out the analysis of Atara Biotherapeutics Correlation against competitors.
For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.

Atara Biotherapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets119.2 M125.5 M215.5 M
Slightly volatile
Other Current Liabilities25.4 M24.4 M20.7 M
Slightly volatile
Total Current Liabilities162.5 M154.8 M58.4 M
Slightly volatile
Other Liabilities131.8 M125.5 M41.1 M
Slightly volatile
Property Plant And Equipment Net42.4 M47.3 M34.8 M
Slightly volatile
Accounts Payable6 M5 M4.9 M
Slightly volatile
Cash27.3 M28.8 M51.7 M
Slightly volatile
Non Current Assets Total44.6 M50.8 M36.6 M
Slightly volatile
Non Currrent Assets Other2.1 M3.6 M1.8 M
Slightly volatile
Other Assets1.091.151.8 M
Pretty Stable
Cash And Short Term Investments46.4 M48.9 M163.7 M
Pretty Stable
Common Stock Total Equity12.1 K11.5 K5.7 K
Slightly volatile
Common Stock Shares Outstanding9 M8.6 M2.9 M
Slightly volatile
Liabilities And Stockholders Equity119.2 M125.5 M215.5 M
Slightly volatile
Non Current Liabilities Total50.8 M82.6 M44 M
Slightly volatile
Other Current Assets8.8 M11.8 M7.3 M
Slightly volatile
Total Liabilities249.2 M237.3 M104.5 M
Slightly volatile
Property Plant And Equipment Gross45.2 M67.2 M38.1 M
Slightly volatile
Total Current Assets70.9 M74.6 M178.7 M
Pretty Stable
Common Stock1.1 K1.1 K4 K
Slightly volatile
Property Plant Equipment6.9 M7.2 M19.6 M
Pretty Stable
Net Tangible Assets287 M145.6 M202.7 M
Slightly volatile
Short Term Investments14.9 M15.7 M130.9 M
Pretty Stable
Capital Surpluse1.1 B2.1 B938.6 M
Slightly volatile
Non Current Liabilities Other37.2 M48.2 M25 M
Slightly volatile
Short and Long Term Debt Total32.1 M50.4 M18.8 M
Slightly volatile
Short and Long Term Debt400 K450 K491.2 K
Slightly volatile
Short Term Debt16.8 M16 M4.9 M
Slightly volatile
Capital Stock8559005.4 K
Very volatile
Long Term Debt Total195.2 K219.6 K239.7 K
Slightly volatile
Capital Lease Obligations42.1 M50.4 M27.3 M
Slightly volatile
Net Receivables1.6 M1.7 M5.5 M
Slightly volatile

Atara Biotherapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.1 M5.8 M3.8 M
Slightly volatile
Selling General Administrative47 M45.9 M38.4 M
Slightly volatile
Other Operating Expenses199.2 M244.2 M166 M
Slightly volatile
Research Development149.6 M174.2 M124.2 M
Slightly volatile
Total Operating Expenses196.7 M220.1 M162.7 M
Slightly volatile
Non Operating Income Net Other63.1 M60.1 M17.6 M
Slightly volatile
Interest Income3.1 M2.4 M2.3 M
Slightly volatile
Reconciled Depreciation6.2 M5.8 M3.7 M
Slightly volatile
Selling And Marketing Expenses888.8 K999.9 K1.1 M
Slightly volatile

Atara Biotherapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation32.1 M31.1 M26.2 M
Slightly volatile
Capital Expenditures268.8 K282.9 K5.1 M
Very volatile
Total Cash From Financing Activities136.3 M68.2 M108.6 M
Pretty Stable
End Period Cash Flow27.5 M29 M53.5 M
Pretty Stable
Begin Period Cash Flow28.4 M29.9 M51 M
Slightly volatile
Depreciation4.2 M5.8 M3.3 M
Slightly volatile
Change To Netincome3.9 M4.1 M16.3 M
Pretty Stable
Issuance Of Capital Stock51.3 M54 M237 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.840.8952.061
Slightly volatile
Days Sales Outstanding3.593.78112
Slightly volatile
Stock Based Compensation To Revenue0.230.242.2705
Slightly volatile
Capex To Depreciation0.05320.0563.4718
Pretty Stable
EV To Sales1.01.0649.5887
Slightly volatile
Inventory Turnover1.151.771.0417
Slightly volatile
Days Of Inventory On Hand321213371
Slightly volatile
Payables Turnover5.914.336.2513
Slightly volatile
Sales General And Administrative To Revenue0.340.363.2096
Slightly volatile
Research And Ddevelopement To Revenue1.281.3511.8049
Slightly volatile
Capex To Revenue0.00210.00220.3798
Slightly volatile
Cash Per Share6.26.53189
Slightly volatile
Days Payables Outstanding82.8987.254.4 K
Slightly volatile
Income Quality0.560.720.636
Slightly volatile
Current Ratio0.530.5510.6306
Slightly volatile
Receivables Turnover82.2278.329.2295
Slightly volatile
Capex Per Share0.03590.03782.9019
Very volatile
Revenue Per Share8.0515.57.2659
Slightly volatile
Interest Debt Per Share6.835.824.4569
Slightly volatile
Debt To Assets0.380.360.1077
Slightly volatile
Operating Cycle162170166
Slightly volatile
Days Of Payables Outstanding82.8987.254.4 K
Slightly volatile
Ebt Per Ebit1.311.181.5075
Slightly volatile
Quick Ratio0.440.4610.6102
Slightly volatile
Net Income Per E B T1.091.155.7971
Slightly volatile
Cash Ratio0.20.214.1639
Slightly volatile
Days Of Inventory Outstanding321213371
Slightly volatile
Days Of Sales Outstanding3.593.78112
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.161.151.0563
Slightly volatile
Fixed Asset Turnover2.962.820.763
Slightly volatile
Debt Ratio0.380.360.1077
Slightly volatile
Price Sales Ratio0.840.8952.061
Slightly volatile
Asset Turnover1.121.060.2414
Slightly volatile

Atara Biotherapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap95.3 M62.5 M79.5 M
Slightly volatile

Atara Fundamental Market Drivers

Forward Price Earnings3.6337
Cash And Short Term Investments42.5 M

Atara Upcoming Events

14th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Atara Biotherapeutics Financial Statements

Atara Biotherapeutics stakeholders use historical fundamental indicators, such as Atara Biotherapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Atara Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Atara Biotherapeutics' assets and liabilities are reflected in the revenues and expenses on Atara Biotherapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Atara Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue109.4 M114.8 M
Total Revenue148.3 M155.7 M
Cost Of Revenue24.2 M25.4 M
Stock Based Compensation To Revenue 0.24  0.23 
Sales General And Administrative To Revenue 0.36  0.34 
Research And Ddevelopement To Revenue 1.35  1.28 
Revenue Per Share 15.50  8.05 
Ebit Per Revenue(0.58)(0.61)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc
When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:
How To Invest In Atara
Details
Is Atara Stock a good investment?
Details
What is Atara Biotherapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Atara Biotherapeutics Correlation against competitors.
For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
2.86
Revenue Per Share
12.858
Quarterly Revenue Growth
(0.91)
Return On Assets
0.3086
Return On Equity
(20.15)
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY